Calmark's product Neo-Bilirubin can now be used for capillary sampling
Calmark Sweden AB announces today that their instruments can now also be used for blood from capillary sampling. The conclusion is based on the study carried out in Greece in 2023. In Sweden, venous sampling of newborn children is the most used, but in several countries in the world capillary sampling of newborn children is a common method. This change is an important step to reach more markets.
Calmark's product Neo-Bilirubin has previously only been recommended for venous samples, i.e. sticking a vessel on the hand or arm. In Sweden, it is the most common method of taking blood samples from children. In many countries, however, capillary sampling, pricking the finger or heel, is used as a method for sampling newborns.
In 2023, a study was completed in Greece comparing the results of capillary samples and venous samples analyzed on Calmark Neo-Bilirubin, these samples were also compared with the laboratory analysis.
The study has been presented as a poster at a congress in 2023 and is in process for publication.
"Many customers have requested to also use capillary samples for measuring bilirubin, because they have that routine. It is important for us to always try to develop our products and meet customers' needs. This approval can open up several markets", comments CEO Anna Söderlund.
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company that manufactures and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, is CE marked and measures the bilirubin level in whole blood for jaundice detection in newborns. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product offers a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
Tags: